A sprayable intranasal mRNA COVID-19 vaccine, CVXGA1 by CyanVac LLC, showed effectiveness in Phase 1 trials per Science Advances. Critics question the trial’s design and small sample size. Journalist Sonia Elijah warns of viral shedding risks exposing unvaccinated people, unexamined in the study. Karl Jablonowski, Ph.D., says CVXGA1’s parainfluenza virus vector is self-spreading, raising safety concerns without informed consent or medical precautions.
Sprayable COVID Vaccine Trial Raises ‘Significant Safety Concerns’
